Fifty years after King was assassinated, we review King's lesser known legacy and how it is used against activists today.
Guest Host: Jen Golbeck
The chief executive of a pharmaceutical company caused a public outcry when he acquired sole U.S. rights to distribute a lifesaving drug and raised the price by more than 5000 percent. But the issue goes well beyond one company and one former hedge fund manager. A number of companies have been quietly cornering the market on older, off-patent drugs–and hiking prices. We speak with a medical historian about the economics of drug pricing, and why “generic” doesn’t guarantee competition.
- Jeremy Greene MD; Professor of Medicine and the History of Medicine, Johns Hopkins University School of Medicine; Author, “Generic: The Unbranding of Modern Medicine.”
Most Recent Shows
While there are hundreds of streets named for Dr. Martin Luther King, Jr. around the country and the region, they are often in economically depressed and racially segregated neighborhoods. We explore Martin Luther King, Jr. Avenue in the District, which is about to undergo major development.
Metro General Manager Paul Wiedefeld and Montgomery County Executive Ike Leggett join us in studio.
D.C. Council unanimously passed a plan to publicly finance political campaigns. What does it offer district residents?